Annual CFI
$88.80 M
+$308.02 M+140.51%
31 December 2023
Summary:
Monte Rosa Therapeutics annual cash flow from investing activities is currently $88.80 million, with the most recent change of +$308.02 million (+140.51%) on 31 December 2023. During the last 3 years, it has risen by +$92.19 million (+2720.27%). GLUE annual CFI is now at all-time high.GLUE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$37.75 M
+$98.91 M+161.72%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly cash flow from investing activities is currently $37.75 million, with the most recent change of +$98.91 million (+161.72%) on 30 September 2024. Over the past year, it has increased by +$2.12 million (+5.95%). GLUE quarterly CFI is now at all-time high.GLUE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$741.00 K
+$2.12 M+153.70%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM cash flow from investing activities is currently $741.00 thousand, with the most recent change of +$2.12 million (+153.70%) on 30 September 2024. Over the past year, it has dropped by -$19.82 million (-96.40%). GLUE TTM CFI is now -99.17% below its all-time high of $88.80 million, reached on 31 December 2023.GLUE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +140.5% | +6.0% | -96.4% |
| 3 y3 years | +2720.3% | +2336.3% | +109.5% |
| 5 y5 years | - | - | - |
GLUE Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +140.5% | at high | +120.9% | -99.2% | +100.3% |
| 5 y | 5 years | at high | +140.5% | at high | +120.9% | -99.2% | +100.3% |
| alltime | all time | at high | +140.5% | at high | +120.9% | -99.2% | +100.3% |
Monte Rosa Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $37.75 M(-161.7%) | $741.00 K(-153.7%) |
| June 2024 | - | -$61.16 M(-720.7%) | -$1.38 M(-101.8%) |
| Mar 2024 | - | $9.85 M(-31.1%) | $78.33 M(-11.8%) |
| Dec 2023 | $88.80 M(-140.5%) | $14.30 M(-59.9%) | $88.80 M(+331.8%) |
| Sept 2023 | - | $35.63 M(+92.1%) | $20.57 M(+42.6%) |
| June 2023 | - | $18.55 M(-8.7%) | $14.43 M(-178.5%) |
| Mar 2023 | - | $20.33 M(-137.7%) | -$18.37 M(-91.6%) |
| Dec 2022 | -$219.22 M | -$53.94 M(-282.9%) | -$219.22 M(+30.2%) |
| Sept 2022 | - | $29.49 M(-307.0%) | -$168.33 M(-15.6%) |
| June 2022 | - | -$14.25 M(-92.1%) | -$199.50 M(+6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$180.52 M(+5824.5%) | -$187.96 M(+1847.1%) |
| Dec 2021 | -$9.65 M(+184.8%) | -$3.05 M(+80.5%) | -$9.65 M(+23.9%) |
| Sept 2021 | - | -$1.69 M(-37.5%) | -$7.79 M(+10.8%) |
| June 2021 | - | -$2.70 M(+21.8%) | -$7.03 M(+25.8%) |
| Mar 2021 | - | -$2.22 M(+86.9%) | -$5.59 M(+65.0%) |
| Dec 2020 | -$3.39 M(+144.7%) | -$1.19 M(+27.5%) | -$3.39 M(+53.8%) |
| Sept 2020 | - | -$930.00 K(-26.2%) | -$2.20 M(+73.1%) |
| June 2020 | - | -$1.26 M(+9592.3%) | -$1.27 M(+9692.3%) |
| Mar 2020 | - | -$13.00 K | -$13.00 K |
| Dec 2019 | -$1.39 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual CFI year-on-year change?
- What is Monte Rosa Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly CFI year-on-year change?
- What is Monte Rosa Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM CFI year-on-year change?
What is Monte Rosa Therapeutics annual cash flow from investing activities?
The current annual CFI of GLUE is $88.80 M
What is the all time high annual CFI for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual cash flow from investing activities is $88.80 M
What is Monte Rosa Therapeutics annual CFI year-on-year change?
Over the past year, GLUE annual cash flow from investing activities has changed by +$308.02 M (+140.51%)
What is Monte Rosa Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of GLUE is $37.75 M
What is the all time high quarterly CFI for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly cash flow from investing activities is $37.75 M
What is Monte Rosa Therapeutics quarterly CFI year-on-year change?
Over the past year, GLUE quarterly cash flow from investing activities has changed by +$2.12 M (+5.95%)
What is Monte Rosa Therapeutics TTM cash flow from investing activities?
The current TTM CFI of GLUE is $741.00 K
What is the all time high TTM CFI for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM cash flow from investing activities is $88.80 M
What is Monte Rosa Therapeutics TTM CFI year-on-year change?
Over the past year, GLUE TTM cash flow from investing activities has changed by -$19.82 M (-96.40%)